Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | HAVCR2 | Q8TDQ0 | 12/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876056 | 0.90 | NPC1 (0.56) | NPC1RAB9AHAVCR2CYP3A4MAPT | |
| SCHEMBL19131014 | 0.80 | S1PR1 (0.58) | NPC1RAB9AHAVCR2CYP3A4MAPT | |
| SCHEMBL12172008 | 0.80 | S1PR1 (0.60) | NPC1RAB9AHAVCR2MAPTKMT2A | |
| SCHEMBL4875581 | 0.77 | NPC1 (0.54) | NPC1RAB9AHAVCR2MAPTHSD17B10 | |
| SCHEMBL6193033 | 0.77 | HAVCR2 (0.60) | NPC1RAB9AHAVCR2MAPTHSD17B10 | |
| SCHEMBL14072336 | 0.76 | NPC1 (0.61) | NPC1RAB9AHAVCR2MAPTSMN1; SMN2 | |
| SCHEMBL1430178 | 0.76 | NR1H4 (0.68) | NPC1RAB9AHAVCR2CYP3A4MAPT | |
| SCHEMBL61028 | 0.75 | NPC1 (0.60) | NPC1RAB9AMAPTTP53SMN1; SMN2 | |
| SCHEMBL1429969 | 0.75 | S1PR1 (0.63) | NPC1RAB9AHAVCR2CYP3A4MAPT | |
| SCHEMBL202628 | 0.74 | PARP1 (0.65) | CHEK2CHEK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432293-B2 | Heterocyclic compounds useful as Nurr-1 activators | NOVARTIS AG (CH) | 2008-10-07 | — | — | US | disclosed |
| US-20060089365-A1 | Heterocyclic compounds useful as nurr-1 activators | NOVARTIS AG (CH) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089365-A1 | Heterocyclic compounds useful as nurr-1 activators | NCOR1, NCOR2, NR4A1 | NPC1 620/4885RAB9A 2603/4885HAVCR2 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.